Pregled bibliografske jedinice broj: 872912
Budget Impact Analysis of Biosimilar Trastuzumab for the Treatment of Breast Cancer in Croatia
Budget Impact Analysis of Biosimilar Trastuzumab for the Treatment of Breast Cancer in Croatia // Applied Health Economics and Health Policy, 15 (2) (2017), 277-286 doi:10.1007/s40258-016-0285-7 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 872912 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Budget Impact Analysis of Biosimilar Trastuzumab for the Treatment of Breast Cancer in Croatia
Autori
Cesarec, August ; Likić, Robert
Izvornik
Applied Health Economics and Health Policy (1175-5652) 15 (2)
(2017);
277-286
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
Budget impact analysis, biosimilar, trastuzumab, Croatia, breast neoplasms
Sažetak
Breast cancer is the most common cancer in women and has considerable impact on healthcare budgets and patients’ quality of life. Trastuzumab (Herceptin®) is a monoclonal antibody directed against the human epidermal growth factor receptor (HER2) for the treatment of breast cancer. Several trastuzumab biosimilars are currently in development. In 2015, trastuzumab was the drug with the highest financial consumption among all drugs in Croatia. This model estimates the 1-year budget impact of the introduction of biosimilar trastuzumab in Croatia.
Izvorni jezik
Engleski
Znanstvena područja
Javno zdravstvo i zdravstvena zaštita, Ekonomija
POVEZANOST RADA
Ustanove:
Ekonomski fakultet, Zagreb,
Medicinski fakultet, Zagreb
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Emerging Sources Citation Index (ESCI)
- Scopus
- MEDLINE
- EconLit
